Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 6/2010

01-12-2010

Islet Versus Pancreas Transplantation in Type 1 Diabetes: Competitive or Complementary?

Authors: Barbara Ludwig, Stefan Ludwig, Anja Steffen, Hans-Detlev Saeger, Stefan R. Bornstein

Published in: Current Diabetes Reports | Issue 6/2010

Login to get access

Abstract

Whole organ pancreas and pancreatic islet transplantation are currently the only forms of clinically available β-cell replacement. Both therapeutic options can provide good glycemic control and prevention or stabilization of diabetic complications, but at the price of permanent immunosuppression. Therefore, the indication for transplantation of type 1 diabetes patients must be balanced carefully and should be restricted to a subgroup of patients with extreme lability of metabolic control and frequent hypoglycemia despite optimal medical therapy.
Literature
1.
Steffes MW, Sibley S, Jackson M, Thomas W: Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26:832–836.CrossRefPubMed
2.
Kelly WD, Lillehei RC, Merkel FK, et al.: Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967, 61:827–837.PubMed
3.
Gruessner AC, Sutherland DE: Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005, 19:433–455.CrossRefPubMed
4.
Venstrom JM, McBride MA, Rother KI, et al.: Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003, 290:2817–2823.CrossRefPubMed
5.
Ballinger WF, Lacy PE: Transplantation of intact pancreatic islets in rats. Surgery 1972, 72:175–186.PubMed
6.
Shapiro AM, Lakey JR, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230–238.CrossRefPubMed
7.
Ojo AO, Meier-Kriesche HU, Hanson JA, et al.: The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001, 71:82–90.CrossRefPubMed
8.
Robertson P, Davis C, Larsen J, et al.: Pancreas transplantation in type 1 diabetes. Diabetes Care 2004, 27(Suppl 1):S105.PubMed
9.
• Sollinger HW, Odorico JS, Becker YT, et al.: One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg 2009, Aug 27 [Epub ahead of print]. This paper shows the largest cohort of SPK transplants at a single center ever with the longest follow-up period of more than 20 years. This is an impressive report by Dr. Sollinger, one of the true pioneers in pancreas transplantation, sharing his tremendous experience in the pancreas transplant field.
10.
Fioretto P, Steffes MW, Sutherland DE, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69–75.CrossRefPubMed
11.
Coppelli A, Giannarelli R, Vistoli F, et al.: The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 2005, 28:1366–1370.CrossRefPubMed
12.
Giannarelli R, Coppelli A, Sartini M, et al.: Effects of pancreas-kidney transplantation on diabetic retinopathy. Transpl Int 2005, 18:619–622.CrossRefPubMed
13.
Koznarova R, Saudek F, Sosna T, et al.: Beneficial effect of pancreas and kidney transplantation on advanced diabetic retinopathy. Cell Transplant 2000, 9:903–908.PubMed
14.
Gaber AO, Oxley D, Karas J, et al.: Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig Dis 1991, 9:437–443.CrossRefPubMed
15.
Hathaway DK, Abell T, Cardoso S, et al.: Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation 1994, 57:816–822.CrossRefPubMed
16.
Perkins BA, Bril V: Diagnosis and management of diabetic neuropathy. Curr Diab Rep 2002, 2:495–500.CrossRefPubMed
17.
Morath C, Zeier M, Dohler B, et al.: Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol 2008, 19:1557–1563.CrossRefPubMed
18.
Coppelli A, Giannarelli R, Mariotti R, et al.: Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients. Transplantation 2003, 76:974–976.CrossRefPubMed
19.
Fiorina P, La Rocca E, Astorri E, et al: Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care 2000, 23:1804–1810.CrossRefPubMed
20.
Fiorina P, La Rocca E, Venturini M, et al.: Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes 2001, 50:496–501.CrossRefPubMed
21.
Jukema JW, Smets YF, van der Pijl JW, et al.: Impact of simultaneous pancreas and kidney transplantation on progression of coronary atherosclerosis in patients with end-stage renal failure due to type 1 diabetes. Diabetes Care 2002, 25:906–911.CrossRefPubMed
22.
Larsen JL, Colling CW, Ratanasuwan T, et al.: Pancreas transplantation improves vascular disease in patients with type 1 diabetes. Diabetes Care 2004, 27:1706–1711.CrossRefPubMed
23.
Larsen JL, Ratanasuwan T, Burkman T, et al.: Carotid intima media thickness decreases after pancreas transplantation. Transplantation 2002, 73:936–940.CrossRefPubMed
24.
Luan FL, Miles CD, Cibrik DM, Ojo AO: Impact of simultaneous pancreas and kidney transplantation on cardiovascular risk factors in patients with type 1 diabetes mellitus. Transplantation 2007, 84:541–544.CrossRefPubMed
25.
Ryan EA, Paty BW, Senior PA, et al.: Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060–2069.CrossRefPubMed
26.
Leitao CB, Tharavanij T, Cure P, et al.: Restoration of hypoglycemia awareness after islet transplantation. Diabetes Care 2008, 31:2113–2115.CrossRefPubMed
27.
Rickels MR, Schutta MH, Markmann JF, et al.: {beta}-Cell function following human islet transplantation for type 1 diabetes. Diabetes 2005, 54:100–106.CrossRefPubMed
28.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.
29.
• Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559. This is a highly controversial large multicenter study (ACCORD) that investigated the effect of intensive insulin therapy on cardiovascular events in type 2 diabetes patients. The initial conclusion of increased risk by rigorous glucose lowering provoked the whole diabetes world.CrossRefPubMed
30.
Fiorina P, Gremizzi C, Maffi P, et al.: Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 2005, 28:1358–1365.CrossRefPubMed
31.
Fiorina P, Folli F, Zerbini G, et al.: Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003, 14:2150–2158.CrossRefPubMed
32.
Lee TC, Barshes NR, O’Mahony CA, et al.: The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy. Transplant Proc 2005, 37:2263–2265.CrossRefPubMed
33.
de Mattos AM, Olyaei AJ, Bennett WM: Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000, 35:333–346.CrossRefPubMed
Metadata
Title
Islet Versus Pancreas Transplantation in Type 1 Diabetes: Competitive or Complementary?
Authors
Barbara Ludwig
Stefan Ludwig
Anja Steffen
Hans-Detlev Saeger
Stefan R. Bornstein
Publication date
01-12-2010
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 6/2010
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-010-0146-y

Other articles of this Issue 6/2010

Current Diabetes Reports 6/2010 Go to the issue

ReviewPaper

Getting (the Most) Out of the Research Business: Interventions for Youth with T1DM

Clinical Trial Report

Preconception Counseling for Adolescent Females with Type 1 Diabetes: The READY-Girls Program

ReviewPaper

Patient Web Portals to Improve Diabetes Outcomes: A Systematic Review

ReviewPaper

The Genetics of Insulin Resistance: Where’s Waldo?

ReviewPaper

Biological Basis of Depression in Adults with Diabetes

ReviewPaper

Genetics of Diabetes Complications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits